论文部分内容阅读
目的为延长药物在眼部的作用时间、增强治疗效果,制备阿西替尼眼用复合药膜用于眼表损伤修复、抗感染及抑制角膜新生血管。方法以阿西替尼为模型药物,用流延成膜技术结合钙离子交联制备载药复合膜,用高效液相色谱(HPLC)法测定药物含量,考察复合药膜体外药物释放。结果复合药膜呈透明状,厚度为(85±11)μm,直径200μm阿西替尼载药膜片载药量为每片(6.5±0.8)μg,溶解性好,角膜组织相容性良好。结论经初步工艺优化,成功制备阿西替尼眼用复合药膜。复合药膜具有药物缓释功能,大大增加药物在眼组织中停留时间。
The purpose is to prolong the role of drugs in the eye time and enhance the therapeutic effect of preparation of axitinib ophthalmic composite membrane for ocular injury repair, anti-infection and inhibition of corneal neovascularization. Methods Axitinib was used as a model drug, and the drug-loaded composite membrane was prepared by casting-film-forming technique combined with calcium ion. The drug content was determined by high performance liquid chromatography (HPLC) and drug release in vitro was investigated. Results The composite membrane was transparent with a thickness of (85 ± 11) μm. The diameter of the loaded membrane of axitinib with a diameter of 200 μm was 6.5 ± 0.8 μg, with good solubility and good corneal histocompatibility . Conclusion The initial process optimization, the successful preparation of axitinib ophthalmic composite membrane. Compound drug film with drug release function, greatly increasing drug retention in the eye tissue time.